Rabourn Amy Zaremba - 23 Apr 2026 Form 4 Insider Report for Opus Genetics, Inc. (IRD)

Reporting relationship: Head of Fin. Quality Assurance
Issuer ticker: IRD
Reported as of: 23 Apr 2026
Net transaction value: -$8,540
SEC form: 4
Accepted by SEC: 27 Apr 2026, 16:27:53 UTC
Prior SEC filing: 18 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Amy Rabourn

Key filing fact

Rabourn Amy Zaremba filed Form 4 for Opus Genetics, Inc. (IRD) on 27 Apr 2026.

Key facts

This page summarizes Rabourn Amy Zaremba's Form 4 filing for Opus Genetics, Inc. (IRD).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 27 Apr 2026, 16:27.

Change

Previous filing in this sequence was filed on 18 Mar 2026.
Current net transaction value: -$8,540.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001832343 Primary reporting owner

Zaremba Rabourn Amy

Relationship: Head of Fin. Quality Assurance
Address: C/O OPUS GENETICS, INC., 8 DAVIS DRIVE, SUITE 220, DURHAM
Signature: /s/ Amy Rabourn
Signature date: 27 Apr 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

IRD transaction

Common Stock

Sale

Transaction value: $8,540
Shares: -1,641
Change %: -0.86%
Price: $5.20
Shares after: 188,671
Date: 23 Apr 2026
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The shares reported on this line were sold automatically on behalf of the Reporting Person, as required by the Company to satisfy tax withholding obligations that arose in connection with a vesting and settlement event from a restricted stock units award. This transaction does not represent a discretionary trade by the Reporting Person.

Footnote F2

The price in column 4 represents the weighted average price. The shares were sold in multiple transactions at prices ranging from $5.2038 to $5.2051, inclusive. The Reporting Person undertakes to provide the issuer, any securityholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.